Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy

Oncology

Volumn 66, Issue 5, 2004, Pages 388-394

  Martin Richard, M ^a,d   Munoz M ^a,b   Albanell, J ^a,b   Colomo, L ^c,d   Bellet, M ^a   Rey, M J ^c   Tabernero, J ^a   Alonso, C ^a   Cardesa, A ^c   Gascon, P ^a,b   Fernandez, P L ^a,c  

^a Servicio de Oncologia Medica ^*  (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Breast cancer; Doxorubicin; HER2; p53; Predictive factor; Topoisomerase II

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME SUBUNIT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASES, TYPE II; DOXORUBICIN; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 4444249420     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079487     Document Type: Article

References (25)

1. Hamilton A, Piccart M: The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. Ann Oncol 2000;11:647-663.
2. Piccart MJ, Awada A: State-of-the-art chemotherapy for advanced breast cancer. Semin Oncol 2000;27:3-12.
3. Harris LN, Yang L, Liotcheva V, et al: Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy. Clin Cancer Res 2001;7:1497-1504.
4. Naidu R, Yadav M, Nair S, Kutty KK: Immunohistochemical analysis of p53 expression in primary breast carcinomas. Anticancer Res 1998;18:65-70.
5. Davidoff AM, Kerns BJ, Pence JC, Marks JR, Iglehart JD: p53 alterations in all stages of breast cancer. J Surg Oncol 1991;48:260-267.
6. Coon JS, Marcus E, Gupta-Burt S, et al: Amplification and overexpression of topoisomerase II alpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002;8:1061-1067.
7. Dhawan V, Swaffar DS: A unique paclitaxel-mediated modulation of the catalytic activity of topoisomerase II alpha. Anticancer Drugs 1999;10:397-404.
8. Sobin LH WC: TNM Classification of Malignant Tumours. New York, Wiley-Liss, 1997.
9. Jares P, Rey MJ, Fernandez PL, et al: Cyclin D1 and retinoblastoma gene expression in human breast carcinoma: Correlation with tumour proliferation and oestrogen receptor status. J Pathol 1997;182:160-166.
10. Jarvinen TA, Holli K, Kuukasjarvi T, Isola JJ: Predictive value of topoisomerase II alpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 1998;77:2267-2273.
11. Durbecq V, Di Leo A, Cardoso F, et al: Comparison of topoisomerase-II alpha gene status between primary breast cancer and corresponding distant metastatic sites. Breast Cancer Res Treat 2003;77:199-204.
12. Di Leo A, Gancberg D, Larsimont. D, et al: HER2 amplification and topoisomerase II alpha gene aberration as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5 fluorouracil. Clin Cancer Res 2002;8:1107-1116.
13. Jarvinen TA, Tanner M, Rantanen V, et al: Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000;156:839-847.
14. Muss HB, Thor AD, Berry DA, et al: c-erbB-2 expression and response to adjuvant therapy in women with node- positive early breast cancer. N Engl J Med 1994;330:1260-1266.
15. Thor AD, Berry DA, Budman DR, et al: erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:1346-1360.
16. Paik S, Bryant J, Park C, et al: erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:1361-1370.
17. Petit T, Borel C, Ghnassia JP, et al: Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res 2001;7:1577-1581.
18. Ravdin PM: Is Her2 of value in identifying patients who particularly benefit from anthracyclines during adjuvant therapy? A qualified yes. J Natl Cancer Inst Monogr 2001;30:80-84.
19. Colomer R, Montero S, Lluch A, et al: Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 2000;6:2356-2362.
20. Schneider J, Lucas R, Sanchez J, Ruibal A, Tejerina A, Martin M: Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: Correlation with the response to therapy and the expression of MDR1 and LRP. Anticancer Res 2000;20:4373-4377.
21. Vargas-Roig LM, Gago FE, Tello O, Martin de Civetta MT, Ciocca DR: c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 1999;84:129-134.
22. Jarvinen TA, Tanner M, Barlund M, Borg A, Isola J: Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 1999;26:142-150.
23. Dunkern TR, Wedemeyer I, Baumgartner M, Fritz G, Kaina B: Resistance of p53 knockout cells to doxorubicin is related to reduced formation of DNA strand breaks rather than impaired apoptotic signaling. DNA Repair (Amst) 2003;2:49-60.
24. Bertheau P, Plassa F, Espie M, et al: Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 2002;360:852-854.
25. Bash-Babula J, Toppmeyer D, Labassi M, et al: A Phase I/pilot study of sequential doxorubicin/vinorelbine: Effects on p53 and microtubule-associated protein 4. Clin Cancer Res 2002;8:1057-1064.